FLT3 and acute myeloid leukemia: In the study of Fleischmann et al., pre-treatment with N-glycosylation inhibitors (tunicamycin or 2-deoxy-D-glucose) led to intracellular retention of FLT3-ITD, and the susceptibility of FLT3-ITD-expressing AML cells to 17-AAG (HSP90 inhibitor) was increased.